+919405117673
Vincristine 1mg Injection Exporter from India | Global Supply by Cordium Pharmaceuticals Pvt Ltd
Cordium Pharmaceuticals Pvt Ltd is a trusted global exporter and supplier of Vincristine 1mg Injection, delivering high-quality oncology-grade pharmaceutical products from India to international markets including the United States, United Kingdom, Germany, Netherlands, United Arab Emirates (UAE), South Africa, and Brazil with reliable and fast export support.

💉 About Vincristine 1mg Injection

Vincristine is an anti-cancer (chemotherapy) medication belonging to the vinca alkaloid class. It is widely used in oncology treatment protocols under strict medical supervision.

📌 Medical Usage

Vincristine 1mg Injection is commonly used in the treatment of:

Acute lymphoblastic leukemia (ALL)
Hodgkin’s and Non-Hodgkin’s lymphoma
Pediatric cancers (as part of combination therapy)
Solid tumors (as prescribed in oncology protocols)
⚠️ Dosage Information
Dosage is strictly determined by an oncologist
Administered via intravenous (IV) injection only
Dose varies based on body surface area, cancer type, and treatment protocol
Should only be given in hospital or clinical settings by trained healthcare professionals
⚠️ Side Effects

Possible side effects may include:

Nerve damage (peripheral neuropathy)
Constipation or gastrointestinal discomfort
Hair loss (temporary alopecia)
Fatigue and weakness
Reduced blood cell counts
Injection site irritation (rare)

Medical supervision is essential during therapy to monitor and manage adverse effects.

🌍 Global Export & Supply

Cordium Pharmaceuticals Pvt Ltd ensures:

WHO-GMP certified quality standards
Secure pharmaceutical packaging
Fast global export logistics
Bulk & hospital supply support
Compliance with international pharma regulations
📦 Export Destinations

Fast delivery available to:
USA | Germany | United Kingdom | Netherlands | South Africa | United Arab Emirates | Brazil

📞 Contact for Orders & Export Inquiry

📱 WhatsApp: +91-9405117673
📧 Email: info@cordiumpharma.com
Apr 18th, 2026 6:44 PM

Keywords